RxDoctor Payments Data

Harb Rank, MD

General Practice · Lynchburg, VANPI 1356366645

Payments from drug & device makers

$583in general payments, 2019–2025

Across 37 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$106
  • Sumitomo Pharma America, Inc.$84
  • Pfizer$66
  • Novo Nordisk$60
  • Amarin Pharma, Inc.$51
  • Supernus Pharmaceuticals, Inc.$38
  • plus $178 from 9 others

What the payments were for

  • Food & beverage$56897%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$583 in reported general payments places this provider in the 65th percentile of 2,591 general practice providers in Virginia.

See all general practice providers in Virginia

Medicare billing

Part B allowed, 2024
$163,221
Medicare patients
510
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban167$141,683
XareltoRivaroxaban57$60,421
OzempicSemaglutide41$53,629
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$49,086
JardianceEmpagliflozin50$42,992
MounjaroTirzepatide31$39,164
DovatoDolutegravir Sodium/Lamivudine12$35,103
EntrestoSacubitril/Valsartan28$32,553
JanuviaSitagliptin Phosphate36$32,371
FarxigaDapagliflozin Propanediol37$31,579
TrulicityDulaglutide24$26,767
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$15,848
MyrbetriqMirabegron12$9,765
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$9,330
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$8,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$141,683167 claims
Johnson & JohnsonXarelto$24$60,42157 claims
Novo NordiskOzempic$60$53,62941 claims
Boehringer IngelheimJardiance, Combivent Respimat$15$50,20565 claims
NovartisEntresto$16$32,55328 claims
Sumitomo Pharma America, Inc.Gemtesa$84$6,39811 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$2,860337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,591 general practice providers in Virginia.

Other general practice in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →